





an Open Access Journal by MDPI

Progress and Innovation on Nanosystems for Gene Therapy

Guest Editors:

Dr. Fani Pereira de Sousa

CICS-UBI—Health Science Research Centre, University of Beira Interior, 6200-506 Covilha, Portugal

Dr. Joana Valente

Centre for Rapid and Sustainable Product Development, Polytechnic Institute of Leiria, 2430-028 Leiria, Portugal

Deadline for manuscript submissions:

closed (20 August 2023)

Message from the Guest Editors

Dear Colleagues,

Gene therapy has shown potential for use as a clinical intervention for the treatment of several conditions Currently, this therapy is not limited to the delivery of DNA to cells, but it can also consider other nucleic acids as therapeutic agents. Non-viral vectors. nanocarriers, have offered an ideal platform to be applied as gene delivery systems acting as a realistic alternative to viral vectors for achieving better efficacy and safety in gene therapy. Different types of nanocarriers have been developed, and each shows distinct characteristics. Meanwhile, systemic delivery is a real challenge for these non-viral vectors since they need to survive in the bloodstream without being degraded or captured by cellular defence mechanisms. Also, when reaching the target organ/tissue, the systems must cross the tissue and bind specifically to the target cells. After this internalization process, it is further required to surpass intracellular obstacles, namely by achieving endosomal escape, surpassing cytoplasm traffic, and finally, entering the nucleus. So, the ability of non-viral vectors to overcome these barriers will dictate their efficiency.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us